ADR Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty Sheehan

The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a Food & Drug Law Institute meeting Sept. 12 in Washington, D.C